No recent analyst price targets found for UBT.
Latest News for UBT
Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China
UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk In a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to 19.7% after 24 weeks UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for UBT.
Senate Trading
No Senate trades found for UBT.
U.S. House Trading
No House trades found for UBT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.